[go: up one dir, main page]

SV2002000586A - Formula de dosificacion de la droga accionada por hidrogel ref. pc11095/700006/b - Google Patents

Formula de dosificacion de la droga accionada por hidrogel ref. pc11095/700006/b

Info

Publication number
SV2002000586A
SV2002000586A SV2001000586A SV2001000586A SV2002000586A SV 2002000586 A SV2002000586 A SV 2002000586A SV 2001000586 A SV2001000586 A SV 2001000586A SV 2001000586 A SV2001000586 A SV 2001000586A SV 2002000586 A SV2002000586 A SV 2002000586A
Authority
SV
El Salvador
Prior art keywords
nucleus
hydrogel
ref
drug dosage
water
Prior art date
Application number
SV2001000586A
Other languages
English (en)
Inventor
Leah Elizabeth Appel
Walter C Babcock
Ronald Arthur Bayerinck
Mark Brian Chidlaw
Dwayne Thomas Friesen
Scott Max Herbig
Avinash Govind Thombre
Original Assignee
Pfizer Prod Inc
Curatolo William John
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Curatolo William John filed Critical Pfizer Prod Inc
Publication of SV2002000586A publication Critical patent/SV2002000586A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

UNA FORMA DE DOSIFICACION DE LIBERACION CONTROLADA COMPRENDE UN NUCLEO RECUBIERTO, COMPRENDIENDO EL NUCLEO UNA COMPOSICION QUE CONTIENE FARMACO Y UNA COMPOSICION HINCHABLE CON AGUA Y OCUPANDO CADA UNA REGIONES SEPARADAS DENTRO DEL NUCLEO. EL RECUBRIMIENTO QUE RODEA EL NUCLEO ES PERMEABLE AL AGUA, INSOLUBLE EN AGUA Y TIENE AL MENOS UNA ABERTURA DE SUMINISTRO. SE DESCRIBEN UNA DIVERSIDAS DE CONFIGURACIONES GEOMETRICAS.
SV2001000586A 2000-08-09 2001-08-08 Formula de dosificacion de la droga accionada por hidrogel ref. pc11095/700006/b SV2002000586A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22419900P 2000-08-09 2000-08-09

Publications (1)

Publication Number Publication Date
SV2002000586A true SV2002000586A (es) 2002-10-24

Family

ID=22839665

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2001000586A SV2002000586A (es) 2000-08-09 2001-08-08 Formula de dosificacion de la droga accionada por hidrogel ref. pc11095/700006/b

Country Status (30)

Country Link
US (2) US20030086972A1 (es)
EP (1) EP1326587A2 (es)
JP (1) JP2004505907A (es)
KR (1) KR20030024844A (es)
CN (1) CN1461212A (es)
AP (1) AP2001002237A0 (es)
AU (1) AU2002229141A1 (es)
BG (1) BG107538A (es)
BR (1) BR0113067A (es)
CA (1) CA2418907A1 (es)
DO (1) DOP2001000229A (es)
EA (1) EA200300081A1 (es)
EC (1) ECSP034455A (es)
EE (1) EE200300055A (es)
GT (1) GT200100161A (es)
HR (1) HRP20030082A2 (es)
HU (1) HUP0300722A2 (es)
IL (1) IL154012A0 (es)
IS (1) IS6686A (es)
MA (1) MA26939A1 (es)
MX (1) MXPA03001209A (es)
NO (1) NO20030627L (es)
OA (1) OA12365A (es)
PA (1) PA8524901A1 (es)
PE (1) PE20020307A1 (es)
PL (1) PL360658A1 (es)
SV (1) SV2002000586A (es)
TN (1) TNSN01123A1 (es)
UY (1) UY26876A1 (es)
WO (1) WO2002011702A2 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
GEP20043334B (en) * 1999-12-23 2004-03-10 Pfizer Prod Inc Hydrogel-Driven Drug Dosage Form
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
PL362687A1 (en) 2001-01-12 2004-11-02 Sun Pharmaceutical Industries Limited Spaced drug delivery system
MXPA04002992A (es) 2001-09-28 2005-06-20 Johnson & Johnson Composicion comestible y forma de dosificacion que comprende una cubierta comestible.
AU2003269744A1 (en) * 2002-05-15 2003-12-02 Sun Pharmaceutical Industries Limited Oral osmotic controlled drug delivery system
WO2004026241A2 (en) * 2002-09-20 2004-04-01 Andrx Labs Llc Multistage formulation containing a biguanide and thiazolidindione derivatives
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7807197B2 (en) 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
NZ538842A (en) * 2002-09-28 2008-03-28 Mcneil Ppc Inc Immediate release dosage form comprising a solid core of density 0.9 g/ml surrounded by a shell that is readily soluble to gastrointestinal fluids
FR2850576B1 (fr) * 2003-02-05 2007-03-23 Ethypharm Sa Composition comprenant un melange de principes actifs, et procede de preparation
WO2004108067A2 (en) * 2003-04-03 2004-12-16 Sun Pharmaceutical Industries Limited Programmed drug delivery system
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
AR040157A1 (es) * 2003-06-06 2005-03-16 Rodriguez Julio Cesar Una formulacion en microgranulos para administracion oral en suspension acuosa
MXPA06001506A (es) * 2003-08-04 2006-05-15 Pfizer Prod Inc Formas de dosificacion de inhibidores de la proteina de transferencia de colesteril ester e inhibidores de la hmg-coa reductasa.
US7879354B2 (en) 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US8067029B2 (en) 2004-01-13 2011-11-29 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
EP1845953A1 (en) * 2005-02-03 2007-10-24 Pfizer Products Incorporated Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
WO2006094083A1 (en) * 2005-02-28 2006-09-08 Penwest Pharmaceuticals Co. Controlled release venlafaxine formulations
US20080213381A1 (en) * 2005-03-14 2008-09-04 Pharmaceutical Industries Limited Oral Drug Delivery System
US20080187581A1 (en) * 2005-03-16 2008-08-07 Subhash Pandurang Gore Delivery System For Mulitple Drugs
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
CN100448433C (zh) * 2005-09-21 2009-01-07 广州贝氏药业有限公司 一种克拉霉素肠溶药物组合物
US20070248630A1 (en) * 2006-04-20 2007-10-25 Friden Phillip M Pharmaceutical formulations for iontophoretic methotrexate delivery
SA07280459B1 (ar) * 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
KR20080076382A (ko) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
WO2009122431A2 (en) * 2008-02-15 2009-10-08 Sun Pharma Advanced Research Company Ltd., Oral controlled release tablet
JP2013510135A (ja) * 2009-11-09 2013-03-21 キャプシュゲル・ベルジウム・エヌ・ヴィ 送達担体
CA2793525C (en) 2010-03-19 2014-05-06 Daiichi Sankyo Company, Limited Method for improving dissolution of anticoagulant agent
ES2673182T3 (es) * 2011-08-10 2018-06-20 Daiichi Sankyo Company, Limited Composición farmacéutica que contiene un derivado de diamina
ES2725879T3 (es) * 2013-01-30 2019-09-30 Daewoong Co Ltd Composición farmacéutica para la protección de heridas, para proporcionar una hemostasia o para evitar la adhesión en el tracto gastrointestinal
MA41868A (fr) * 2015-04-01 2018-02-06 Spectrum Brands Inc Pastille retard et procédés s'y rapportant
US10350822B1 (en) * 2018-01-09 2019-07-16 Triastek Inc. Dosage forms with desired release profiles and methods of designing and making thereof
CA3088017A1 (en) * 2018-03-07 2019-09-12 Andrew Xian Chen Aqueous formulations for insoluble drugs
EP4346762A1 (en) * 2021-05-28 2024-04-10 Amgen Inc. Formulations of apremilast
CN113600179B (zh) * 2021-09-16 2023-07-04 山东博霖环保科技发展有限公司 一种脱硝催化剂及其制备方法
JPWO2023063381A1 (es) * 2021-10-14 2023-04-20

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1025765B (it) * 1974-11-18 1978-08-30 Gastaldi Francesco Essiccatore perfezionato a spruzzo
US4187617A (en) * 1978-12-18 1980-02-12 Becker James J Jr Spray dryer
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4624848A (en) * 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5096716A (en) * 1988-09-01 1992-03-17 Alza Corporation Dosage form for administering calcium antagonist nicardipine
US5030452A (en) * 1989-01-12 1991-07-09 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
JPH05178763A (ja) * 1991-02-19 1993-07-20 Nippon Saafuakutanto Kogyo Kk 難溶解性薬物溶解剤組成物
SI9520049A (en) * 1994-05-06 1997-12-31 Pfizer Controlled-release dosage forms of azithromycin
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
WO1999001121A1 (en) * 1997-07-01 1999-01-14 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
PL337804A1 (en) * 1997-07-01 2000-09-11 Pfizer Prod Inc Solubilised compositions of sertralin
DE19747261A1 (de) * 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
CA2346335C (en) * 1998-10-13 2006-04-18 Pfizer Products Inc. Sertraline oral concentrate
DE60042352D1 (de) * 1999-02-10 2009-07-23 Pfizer Prod Inc Osmotisches System zur Verabreichung von Wirkstoffen, die feste amorphe Dispersionen enthalten
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
GT200100039A (es) * 2000-03-16 2001-12-31 Pfizer Inhibidor de la glucogeno fosforilasa.
PL377479A1 (pl) * 2002-12-11 2006-02-06 Pfizer Products Inc. Kontrolowane uwalnianie substancji czynnej do środowiska o wysokiej zawartości tłuszczu

Also Published As

Publication number Publication date
HUP0300722A2 (hu) 2003-11-28
PA8524901A1 (es) 2002-04-25
AP2001002237A0 (en) 2001-09-30
PL360658A1 (en) 2004-09-20
ECSP034455A (es) 2003-03-10
WO2002011702A3 (en) 2002-11-28
US20030086972A1 (en) 2003-05-08
NO20030627L (no) 2003-04-08
EA200300081A1 (ru) 2003-08-28
EP1326587A2 (en) 2003-07-16
DOP2001000229A (es) 2002-09-30
BR0113067A (pt) 2003-07-01
US20040052845A1 (en) 2004-03-18
AU2002229141A1 (en) 2002-02-18
HRP20030082A2 (en) 2003-04-30
TNSN01123A1 (fr) 2005-11-10
CN1461212A (zh) 2003-12-10
BG107538A (bg) 2003-11-28
OA12365A (en) 2006-05-16
IL154012A0 (en) 2003-07-31
CA2418907A1 (en) 2002-02-14
GT200100161A (es) 2002-03-22
JP2004505907A (ja) 2004-02-26
IS6686A (is) 2003-01-16
NO20030627D0 (no) 2003-02-07
MA26939A1 (fr) 2004-12-20
UY26876A1 (es) 2002-03-22
WO2002011702A2 (en) 2002-02-14
MXPA03001209A (es) 2003-06-30
EE200300055A (et) 2004-12-15
KR20030024844A (ko) 2003-03-26
PE20020307A1 (es) 2002-04-23

Similar Documents

Publication Publication Date Title
SV2002000586A (es) Formula de dosificacion de la droga accionada por hidrogel ref. pc11095/700006/b
PA8508901A1 (es) Forma de dosificacion de farmaco en capas impulsada por hidrogel
GT200000222A (es) Forma de dosificacion de farmacos accionada por un hidrogel.
SV2002000248A (es) Composicion farmaceutica suministrando concentracion aumentada de la droga ref. pc10755ajtj/bb
SV2002000195A (es) Compuestos farmaceuticamente activos ref. pcs10342 afae/bb
PE20010053A1 (es) Formulacion de amoxicilina y clavulanato de potasio
SV1999000048A (es) Uso de dihidropiriminas como medicamento y nuevas sustancias ref. lea 32 791-sv
MX9305277A (es) Monohidrato de 5-(2-4(1,2-benzisotiazol-3-il)-1-piperazinil)-etil-6-cloro-1,3-dihidro-2h-indol-2-1-clorhidrato.
DE69531790D1 (de) Duschaufsatz
ES2238941T1 (es) Solvato de hemitartrato de zolpidem.
PE8298A1 (es) Tabletas exentas de aglutinante que contienen tramadol o una sal de tramadol para administracion oral
AR030974A1 (es) Un envase soluble en agua y su preparacion
TR200400228T4 (tr) Psöryazinin tedavisinde kullanılacak maddeler
DOP2001000279A (es) Uso de polimerizados como auxiliares de filtracion y/o estabilizantes.
ES2110628T3 (es) Catalizador vehiculante y su uso.
IT1318514B1 (it) Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
ES2180729T3 (es) Tratamiento terapeutico combinado de las patologias hiperproliferantes.
PA8565201A1 (es) Sistema de suministro osmotico
ES2033169B1 (es) Recipiente para el cultivo de algas y procedimiento para su utilizacion.
HN2000000057A (es) Derivados de i - trifluorometil-4-hidroxi-7-piperidinil- aminometilcromano.
ITRM990309A0 (it) Composizione per il trattamento del prurito uremico e di forme di prurito non riconducibili a lesioni organiche.
ECSP003508A (es) Formas polimorfas de un citrato de azobiciclo [2.2.2] octan-3-amina y sus composiciones farmaceuticas
DK1140810T3 (da) Benzensulfonamidderivater samt deres anvendelse
ES2017694B3 (es) Procedimiento para la aceleracion de la absorcion de agua de betonita, especialmente como material suplemento para arena de moldear.
ES2175314T3 (es) Perfeccionamiento de un estuche giratorio como un tubo de barra de labios.

Legal Events

Date Code Title Description
FD Lapse